(Total Views: 350)
Posted On: 07/10/2020 6:56:55 AM
Post# of 72
https://clinicaltrials.gov/ct2/show/NCT029280...amp;rank=1
So many variables. First Q of 2023 based on the above info. having said that the trial could be stopped early if the interim data is good. Considering there is unmet need it could be approved immediately without the normal 10 month FDA review or even without having to be fast tracked at 6 months.
Glad you stopped in here for a visit. I appreciate your insight on the GNBT board. Don't forget the CC this afternoon! We are expecting information on the new subsidiary NuGenerex Immuno-Oncology.
More to follow on CRXM.
So many variables. First Q of 2023 based on the above info. having said that the trial could be stopped early if the interim data is good. Considering there is unmet need it could be approved immediately without the normal 10 month FDA review or even without having to be fast tracked at 6 months.
Glad you stopped in here for a visit. I appreciate your insight on the GNBT board. Don't forget the CC this afternoon! We are expecting information on the new subsidiary NuGenerex Immuno-Oncology.
More to follow on CRXM.
(0)
(0)Scroll down for more posts ▼
